Literature DB >> 32041800

Effect of Lipidation on the Localization and Activity of a Lysozyme Inhibitor in Neisseria gonorrhoeae.

Stephanie A Ragland1, Mary C Gray1, Elizabeth M Melson1, Melissa M Kendall1, Alison K Criss2.   

Abstract

The Gram-negative pathogen Neisseria gonorrhoeae (gonococcus [Gc]) colonizes lysozyme-rich mucosal surfaces. Lysozyme hydrolyzes peptidoglycan, leading to bacterial lysis. Gc expresses two proteins, SliC and NgACP, that bind and inhibit the enzymatic activity of lysozyme. SliC is a surface-exposed lipoprotein, while NgACP is found in the periplasm and also released extracellularly. Purified SliC and NgACP similarly inhibit lysozyme. However, whereas mutation of ngACP increases Gc susceptibility to lysozyme, the sliC mutant is only susceptible to lysozyme when ngACP is inactivated. In this work, we examined how lipidation contributes to SliC expression, cellular localization, and resistance of Gc to killing by lysozyme. To do so, we mutated the conserved cysteine residue (C18) in the N-terminal lipobox motif of SliC, the site for lipid anchor attachment, to alanine. SliC(C18A) localized to soluble rather than membrane fractions in Gc and was not displayed on the bacterial surface. Less SliC(C18A) was detected in Gc lysates compared to the wild-type protein. This was due in part to some release of the C18A mutant, but not wild-type, protein into the extracellular space. Surprisingly, Gc expressing SliC(C18A) survived better than SliC (wild type)-expressing Gc after exposure to lysozyme. We conclude that lipidation is not required for the ability of SliC to inhibit lysozyme, even though the lipidated cysteine is 100% conserved in Gc SliC alleles. These findings shed light on how members of the growing family of lysozyme inhibitors with distinct subcellular localizations contribute to bacterial defense against lysozyme.IMPORTANCE Neisseria gonorrhoeae is one of many bacterial species that express multiple lysozyme inhibitors. It is unclear how inhibitors that differ in their subcellular localization contribute to defense from lysozyme. We investigated how lipidation of SliC, an MliC (membrane-bound lysozyme inhibitor of c-type lysozyme)-type inhibitor, contributes to its localization and lysozyme inhibitory activity. We found that lipidation was required for surface exposure of SliC and yet was dispensable for protecting the gonococcus from killing by lysozyme. To our knowledge, this is the first time the role of lipid anchoring of a lysozyme inhibitor has been investigated. These results help us understand how different lysozyme inhibitors are localized in bacteria and how this impacts resistance to lysozyme.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MliC; Neisseria gonorrhoeaezzm321990; antimicrobial; lipoprotein; lysozyme; lysozyme inhibitors; secretion

Mesh:

Substances:

Year:  2020        PMID: 32041800      PMCID: PMC7099142          DOI: 10.1128/JB.00633-19

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  47 in total

Review 1.  Lipoproteins of bacterial pathogens.

Authors:  A Kovacs-Simon; R W Titball; S L Michell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Structural basis for the recognition of lysozyme by MliC, a periplasmic lysozyme inhibitor in Gram-negative bacteria.

Authors:  Soohwan Yum; Moon Jong Kim; Yongbin Xu; Xiao Ling Jin; Hee Young Yoo; Ji-Won Park; Ji Hee Gong; Kwang-Min Choe; Bok Luel Lee; Nam-Chul Ha
Journal:  Biochem Biophys Res Commun       Date:  2008-11-24       Impact factor: 3.575

3.  Post-transcriptional regulation of target genes by the sRNA FnrS in Neisseria gonorrhoeae.

Authors:  Pooja Tanwer; Susanne Bauer; Elisabeth Heinrichs; Gurudutta Panda; Daman Saluja; Thomas Rudel; Dagmar Beier
Journal:  Microbiology (Reading)       Date:  2017-07-21       Impact factor: 2.777

4.  Bacillus subtilis σ(V) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and D-alanylation of teichoic acids.

Authors:  Veronica Guariglia-Oropeza; John D Helmann
Journal:  J Bacteriol       Date:  2011-09-16       Impact factor: 3.490

5.  The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysozyme resistance and virulence of Enterococcus faecalis.

Authors:  André Le Jeune; Riccardo Torelli; Maurizio Sanguinetti; Jean-Christophe Giard; Axel Hartke; Yanick Auffray; Abdellah Benachour
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

6.  The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme.

Authors:  Emily C Woods; Kathryn L Nawrocki; Jose M Suárez; Shonna M McBride
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

7.  Eep confers lysozyme resistance to enterococcus faecalis via the activation of the extracytoplasmic function sigma factor SigV.

Authors:  Sriram Varahan; Vijayalakshmi S Iyer; William T Moore; Lynn E Hancock
Journal:  J Bacteriol       Date:  2013-05-03       Impact factor: 3.490

8.  Clostridium difficile extracytoplasmic function σ factor σV regulates lysozyme resistance and is necessary for pathogenesis in the hamster model of infection.

Authors:  Theresa D Ho; Kyle B Williams; Yan Chen; Richard F Helm; David L Popham; Craig D Ellermeier
Journal:  Infect Immun       Date:  2014-03-24       Impact factor: 3.441

9.  The Anti-sigma Factor RsiV Is a Bacterial Receptor for Lysozyme: Co-crystal Structure Determination and Demonstration That Binding of Lysozyme to RsiV Is Required for σV Activation.

Authors:  Jessica L Hastie; Kyle B Williams; Lindsey L Bohr; Jon C Houtman; Lokesh Gakhar; Craig D Ellermeier
Journal:  PLoS Genet       Date:  2016-09-07       Impact factor: 5.917

10.  SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection.

Authors:  Ryszard A Zielke; Adriana Le Van; Benjamin I Baarda; Marco F Herrera; Christopher J Acosta; Ann E Jerse; Aleksandra E Sikora
Journal:  PLoS Pathog       Date:  2018-07-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.